Riskpilot← Back to searchSign inGet full accessP5Med AB
ABActiveOrg 5590636923Nåsvägen 9Manufacture of communication equipment · NACE 2630Est. 20160 employees
Revenue 2024
SEK 0
EBITDA margin
—
+10% vs 2023
Equity ratio
89.9%
Financial strength
Net profit 2024
SEK -13K
+80% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -13K | +10% |
| Net profit | SEK -13K | +80% |
| Total assets | SEK 99K | -93% |
| Equity | SEK 89K | -94% |
| Employees | 0 | — |
Legal name
P5Med AB
Org number
5590636923
Legal form
Aktiebolag
NACE code
2630 · Manufacture of communication equipment
Founded
23 maj 2016
Share capital
SEK 60 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Företaget ska bedriva produktutveckling och mjukvaruutveckling inom IT och telekom samt tillhandahållande av IT baserade tjänster online och därmed förenlig verksamhet.
Address
Nåsvägen 9
Email
stefan.hultberg@colooc.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 672 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 531 | −17 | −9 | −15 | −13 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 531 | −17 | −9 | −66 | −13 |
| Net financials | −14 | 767 | — | 0 | 0 |
| Profit before tax | 518 | 749 | −9 | −66 | −13 |
| Tax | −0 | −0 | — | — | — |
| Net profit | 518 | 749 | −9 | −66 | −13 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 331 | 1 596 | 1 578 | 1 512 | 99 |
| Equity | 829 | 1 577 | 1 568 | 1 502 | 89 |
| Long-term debt | 312 | 0 | — | — | — |
| Short-term debt | 191 | 19 | 10 | 10 | 10 |
| Total debt | 503 | 19 | 10 | 10 | 10 |
EBITDA margin
-1346800.0%
This company
15.8%
Market median
-8524151% vs market
20202024
Equity ratio
89.9%
This company
38.2%
Market median
+135% vs market
20202024
Return on equity
-15.2%
This company
18.4%
Market median
-183% vs market
20202024
Net profit margin
-1346000.0%
This company
8.1%
Market median
-16617384% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
PH Audit | Audit | 2022 |
HS Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of P5Med AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Hjalmar Lindblom | Audit | 0 companies |
| Hans Stefan Hultberg | Chief Executive Officer | 0 companies |
| Anna Margareta Hultberg | Deputy Board Member | 0 companies |
| Mats Holger Jansson | Chairman | 0 companies |